Improving survival with metformin: the evidence base today

Area of Science:

• Endocrinology
• Cardiology
• Pharmacology

Background:

• Glycaemic control is crucial for reducing microvascular complications in diabetes.
• Macrovascular disease, a leading cause of mortality in type 2 diabetes, is not solely improved by glycaemic control.
• Metformin's role in managing type 2 diabetes and its associated cardiovascular risks requires further elucidation.

Purpose of the Study:

• To evaluate the impact of metformin on macrovascular complications and mortality in type 2 diabetes.
• To compare the cardiovascular benefits of metformin with other diabetes treatments.
• To establish metformin as a first-line therapy for type 2 diabetes.

Main Methods:

• Analysis of data from the UK Prospective Diabetes Study (UKPDS).
• Comparison of metformin's efficacy against other oral agents, diet, and insulin.
• Review of clinical and experimental studies on metformin's outcomes.
• Retrospective analysis of mortality rates in patients on metformin versus sulfonylurea monotherapy.

Main Results:

• Metformin significantly reduced diabetes-related mortality by 42% (vs. diet).
• Metformin lowered all-cause mortality by 36% and myocardial infarction risk by 39%.
• A 32% reduction in any diabetes-related endpoint was observed with metformin.
• Metformin demonstrated superior cardiovascular protection compared to other treatments achieving similar glycaemic control.

Conclusions:

• Metformin offers significant cardiovascular protection in type 2 diabetes, exceeding its antihyperglycaemic effects.
• Metformin is the preferred first-line drug for type 2 diabetes management due to its benefits in reducing macrovascular complications and mortality.
• The UKPDS findings and supporting studies confirm metformin's critical role in improving long-term outcomes for type 2 diabetes patients.